Focused On-demand Library for Myeloid-derived growth factor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q969H8

UPID:

MYDGF_HUMAN

Alternative names:

Alternative UPACC:

Q969H8; D6W628; O75256; O75272; Q9BTK7; Q9NP69

Background:

The Myeloid-derived growth factor plays a pivotal role in cardiac protection and repair mechanisms, particularly after myocardial infarction (MI). It is a bone marrow-derived monocyte and paracrine-acting protein that not only promotes cardiac myocyte survival but also stimulates adaptive angiogenesis. Its function involves enhancing endothelial cell proliferation through a MAPK1/3-, STAT3-, and CCND1-mediated signaling pathway and inhibiting cardiac myocyte apoptosis via a PI3K/AKT-dependent signaling pathway.

Therapeutic significance:

Understanding the role of Myeloid-derived growth factor could open doors to potential therapeutic strategies. Its involvement in promoting cardiac myocyte survival and stimulating endothelial cell proliferation for angiogenesis highlights its potential as a target for developing treatments aimed at cardiac repair and protection, especially following myocardial infarction.